Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Stock Information for Amylyx Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Amylyx Pharmaceuticals Inc.

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.